A Phase I/II, Randomised, Multicentre, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults (Age 50 to 75 Years)

Trial Profile

A Phase I/II, Randomised, Multicentre, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults (Age 50 to 75 Years)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Eurocine
  • Most Recent Events

    • 08 Aug 2018 Results presented in the Eurocine media release.
    • 25 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 07 Feb 2018 According to an Eurocine media release, study is planned to be conducted at five locations throughout Sweden during the present influenza season.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top